- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03614260
RADIANCE II Pivotal Study: En studie av ReCor Medical Paradise System i stadium II hypertensjon (RADIANCE-II)
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Brussels, Belgia, 1000
- Centre Hospitalier Universitaire Saint-Pierre
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35211
- Cardiology PC
-
-
California
-
Los Angeles, California, Forente stater, 940048
- Cedars Sinai Medical Center
-
-
Connecticut
-
Bridgeport, Connecticut, Forente stater, 06610
- Bridgeport Hospital
-
Stamford, Connecticut, Forente stater, 06904
- Stamford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- MedStar Washington
-
-
Florida
-
Gainsville, Florida, Forente stater, 32605
- The Cardiac and Vascular Institute
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Emory University Hospital Midtown
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Springfield, Illinois, Forente stater, 62794
- Southern Illinois University
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Heart and Vascular Institute
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02120
- The Brigham and Women's Hospital
-
-
Michigan
-
Traverse City, Michigan, Forente stater, 49684
- Munson Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Saint Luke's Health System
-
-
Nevada
-
Reno, Nevada, Forente stater, 89502
- Renown Regional Medical Center
-
-
New Jersey
-
Browns Mills, New Jersey, Forente stater, 08015
- Deborah Heart & Lung Center
-
Hackensack, New Jersey, Forente stater, 07601
- Hackensack University
-
-
New York
-
New York, New York, Forente stater, 10032
- Columbia University Medical Center/NYPH
-
New York, New York, Forente stater, 10075
- Northwell Health Inc.
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- The University of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania Health System
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38163
- The University of Tennessee Health Science Center
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84132
- University of Utah
-
-
Washington
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center
-
-
-
-
-
Bordeaux, Frankrike, 33000
- Hôpital Saint André
-
Lille, Frankrike, 59000
- CHRU de Lille
-
Paris, Frankrike, 75015
- Hôpital Européen Georges-Pompidou (HEGP)
-
-
-
-
-
Galway, Irland, H91 YR71
- University Hospital Galway
-
-
-
-
-
Rotterdam, Nederland, 3015 GD
- Erasmus Medical Center
-
-
-
-
-
Bournemouth, Storbritannia, BH7 7DW
- University Hospitals Dorset NHS Foundation Trust
-
Canterbury, Storbritannia, CT1 3NG
- Kent & Canterbury Hospital
-
Cardiff, Storbritannia
- University Hospital Wales
-
London, Storbritannia, EC1A 7BE
- St Bartholomew's Hospital
-
Newcastle upon Tyne, Storbritannia, NE7 7DN
- Freeman Hospital
-
-
Essex
-
Basildon, Essex, Storbritannia, SS16 5NL
- The Cardiothoracic Centre Basildon University Hospital
-
-
-
-
-
Geneva, Sveits, 1211
- Hôpitaux Universitaires Genève
-
-
-
-
-
Erlangen, Tyskland, D-91054
- University Clinic Erlangen
-
Homburg, Tyskland, D-66421
- University Clinic of Saarland - Homburg
-
Karlsruhe, Tyskland, 76133
- Klinikum Karlsruhe GmbH
-
Konstanz, Tyskland, D-78464
- Klinikum Konstanz
-
Leipzig, Tyskland, D-04289
- Herzzentrum Leipzig GmbH
-
Lübeck, Tyskland, D-23560
- Sana Kliniken Lübeck GmbH
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Previously or currently prescribed antihypertensive therapy
- Average office BP ≥ 140/90 mmHg <180/120 mmHg while stable for at least 4 weeks on 0-2 classes of antihypertensive medication
- Documented daytime ABP ≥ 135/85 mmHg and < 170/105 mmHg after 4-week washout/run-in period
Exclusion Criteria:
- Lacks appropriate renal artery anatomy for treatment
- Known, uncorrected causes of secondary hypertension other than sleep apnea
- Type I diabetes mellitus or uncontrolled Type II diabetes
- eGFR of <40
- Brachial circumference ≥ 42 cm
- Any history of cerebrovascular event or severe cardiovascular event, or history of stable or unstable angina within 12 months prior to consent
- Repeat (>1) hospitalization for hypertensive crisis within 12 months prior to screening period, or any hospitalization for hypertensive crisis within 3 months prior to screening period
- Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- Primary pulmonary hypertension
- Night shift workers
- Pregnant, nursing or planning to become pregnant
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Renal Denervation
Renal Angiogram and Renal Denervation (Paradise Renal Denervation System) |
Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
Andre navn:
|
|
Sham-komparator: Sham Control
Renal Angiogram |
Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Average Daytime Ambulatory Systolic BP
Tidsramme: From baseline to 2 months post-procedure
|
The primary efficacy outcome is the mean change in daytime ambulatory systolic blood pressure at 2 months |
From baseline to 2 months post-procedure
|
|
Percentage of Participants With Major Adverse Events (MAE)
Tidsramme: From baseline to 30 days post-procedure
|
The primary safety composite outcome of major adverse events included death, kidney failure, and major embolic, vascular, cardiovascular, cerebrovascular, and hypertensive events at 30 days. |
From baseline to 30 days post-procedure
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Average 24-hr Ambulatory Systolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average 24-hr ambulatory systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Office Systolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average office systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Home Systolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average home systolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Daytime Ambulatory Diastolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average daytime ambulatory diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average 24-hr Ambulatory Diastolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average 24-hr ambulatory diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Office Diastolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average office diastolic blood pressure |
From baseline to 2 months post-procedure
|
|
Change in Average Home Diastolic BP
Tidsramme: From baseline to 2 months post-procedure
|
Change in average home diastolic blood pressure |
From baseline to 2 months post-procedure
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ajay Kirtane, MD, SM, Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation
- Hovedetterforsker: Prof. Michel Azizi, MD, PhD, Professor of Vascular Medicine, Hypertension Dept. and Clinical Investigation Center, Hôpital Européen Georges Pompidou
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE, Mahfoud F, Lindsey J, Sanghvi K, Todoran TM, Pacella J, Flack J, Daemen J, Sharp ASP, Lurz P, Bloch MJ, Weber MA, Lobo MD, Basile J, Claude L, Reeve-Stoffer H, McClure CK, Kirtane AJ; RADIANCE II Investigators and Collaborators. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023 Feb 28;329(8):651-661. doi: 10.1001/jama.2023.0713.
- Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F, Schmieder RE, Basile J, Bloch MJ, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Claude L, Augustin DA, McClure CK, Kirtane AJ; RADIANCE Investigators. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. 2024 Mar 5;149(10):747-759. doi: 10.1161/CIRCULATIONAHA.123.066941. Epub 2023 Oct 26.
- Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, Lobo MD, Lurz P, Basile J, Bloch MJ, Weber MA, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Sapoval M, Barman NC, Claude L, Augustin D, Thackeray L, Mullin CM, Azizi M; RADIANCE Investigators and Collaborators. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. JAMA Cardiol. 2023 May 1;8(5):464-473. doi: 10.1001/jamacardio.2023.0338.
- Bytyqi V, Kannenkeril D, Striepe K, Bosch A, Karg MV, Schmid A, Schiffer M, Uder M, Schmieder RE. Predicting blood pressure response to renal denervation based on a new approach. J Hypertens. 2025 Mar 1;43(3):413-419. doi: 10.1097/HJH.0000000000003918. Epub 2024 Oct 29.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RADIANCE II Study
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .